Skip to main content
Premium Trial:

Request an Annual Quote

Alere Gets CE Mark for Alere q HIV-1/2 Detect Assay

NEW YORK (GenomeWeb) – Alere announced today that it has received CE marking for a rapid molecular diagnostic test for HIV 1/2 on its Alere q platform.

The assay is a point of care test that detects and distinguishes between strains of HIV virus in less than 60 minutes, the Waltham, Mass.-based diagnostics firm said in a statement. It will be applied toward early infant diagnosis.

The Alere q platform is battery powered, fully automated, and cartridge-based, and does not require sample extraction steps. A multiplex reaction runs on-board controls and distinguishes between HIV 1 subgroup M/N, HIV 1 subgroup O, and HIV 2. The test was validated by five clinics in Mozambique and showed high specificity and sensitivity for diagnosing infants, according to a study in the Journal of Acquired Immune Deficiency Syndromes, the firm said.

Alere launched another point of care isothermal nucleic acid amplification platform last year. Called the Alere i, that system has since received FDA clearance and CLIA waiver for an associated influenza test, as well as $12.9 million in federal funding to develop the system for pandemic influenza.

The technology is also being investigated for potential applications for the diagnosis and monitoring of other infectious diseases, such as hepatitis C, tuberculosis, and Ebola, according to today's statement. The firm described its increased focus on the molecular diagnostics market in an earnings call last month. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.